Background: Sodium glucose co-transporter 2 inhibitor (SGLT2i) is a new arment in
the prevention and treatment of diabetic kidney disease with a potential effect on reducing and preventing
Chronic Kidney Disease (CKD) progression.
Objective: To evaluate the effect of SGLT2 inhibitor in comparison to traditional medication in diabetic
patients with microalbuminuria.
Methods: A total of 60 diabetic patients with microalbuminuria were divided into group I, where
30 patients were treated by traditional medications (RAAS blockers) and group II where 30 patients
were treated by Dapagliflozin added to the traditional medications. All patients were followed
up for 6 months and their Urine Albumin/Creatinine Ratio (UACR) and eGFR changes were
Results: UACR significantly declined after 6 months of treatment in group II with a p-value
<0.001. There were no significant eGFR changes between both groups. Systolic blood pressure decreases
in both groups, but the decrease was highly significant in group II (pvalue<0.001). Diastolic
blood pressure decreases significantly in both groups (p-value<0.001). Also, bodyweight reduced
significantly in group II with a p-value<0.001.
Conclusion: Dapagliflozin, when added to traditional medications (RAAS Blockers), leads to a significant
reduction in microalbuminuria with no significant eGFR changes.